Jose-maria Raya

Santa Cruz De Tenerife, CN, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era.

Survival outcomes and treatment patterns in myelofibrosis in the JAK inhibitor era.

Journal: British journal of haematology

Published: May 14, 2026

Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.

Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis.

Journal: Leukemia

Published: June 19, 2024

The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis.

The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis.

Journal: American journal of hematology

Published: December 04, 2023

Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis.

Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis.

Journal: HemaSphere

Published: October 24, 2023

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis.

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis.

Journal: HemaSphere

Published: September 03, 2022

Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis.

Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis.

Journal: British journal of haematology

Published: July 20, 2022

Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.

Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.

Journal: Cancer

Published: October 29, 2021

Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry.

Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry.

Journal: American journal of hematology

Published: April 18, 2021

Prognostic risk models for transplant decision-making in myelofibrosis.

Prognostic risk models for transplant decision-making in myelofibrosis.

Journal: Annals of hematology

Published: August 21, 2017

Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia.

Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia.

Journal: British journal of haematology

Published: April 19, 2017

Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis.

Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis.

Journal: European journal of haematology

Published: December 19, 2016

The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.

The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.

Journal: Haematologica

Published: February 04, 2014

Showing 1-12 of 12

Last Updated: 09/26/2026